Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03770637 · ClinicalTrials.gov registry record · Phase 2
Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery
A Phase 2 study of Hyperinsulinemic Hypoglycemia, sponsored by Xeris Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 5
- Study locations
NCT03770637 is a Phase 2 study of Hyperinsulinemic Hypoglycemia that has completed, run by Xeris Pharmaceuticals. The registered enrollment target is 14 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT03770637, a Phase 2 study of Hyperinsulinemic Hypoglycemia, has completed, sponsored by Xeris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a double-blind, placebo-controlled Phase 2 study to assess the efficacy, safety and tolerability of Glucagon RTU when administered to subjects with a history of bariatric surgery during episodes of post-postprandial hypoglycemia. Twelve eligible subjects will be randomly assigned to receive Glucagon RTU or placebo at the first of two clinical research center (CRC) visits, followed by the other treatment at the second CRC visit. Subjects will be randomly assigned to either Glucagon RTU or Placebo for the duration of a 12-week Outpatient Stage. A follow-up safety assessment visit will occur 14 to 28 days after a subject's last dose of study drug.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Glucagon RTU
Study Locations (5)
Colorado
- University of Colorado-Denver - Aurora
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Joslin Diabetes Center - Boston
Minnesota
- Mayo Clinic- Rochester - Rochester
North Carolina
- Duke Early Phase Clinical Research - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-05-10 |
| Est. Completion | 2020-02-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03770637
The ClinicalTrials.gov registry entry for NCT03770637 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xeris Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hyperinsulinemic Hypoglycemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03770637 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Colorado, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03770637 about?
NCT03770637 is a clinical study titled "Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery". This is a double-blind, placebo-controlled Phase 2 study to assess the efficacy, safety and tolerability of Glucagon RTU when administered to subjects with a history of bariatric surgery during episodes of post-postprandial hypoglycemia. Twelve eligible subjects will be randomly assigned to receive ...
What is the current status of trial NCT03770637?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2019-05-10. Estimated completion is 2020-02-26.
What conditions does trial NCT03770637 study?
This clinical trial studies the following conditions: Hyperinsulinemic Hypoglycemia.
What interventions are being tested in trial NCT03770637?
The interventions under investigation include: Placebo (OTHER), Glucagon RTU (DRUG).
Who is sponsoring clinical trial NCT03770637?
This trial is sponsored by Xeris Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03770637 being conducted?
This trial has 5 study locations across Colorado, Maryland, Massachusetts, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.